Hikma Pharmaceuticals PLC
LSE:HIK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
UK |
|
M
|
Microstrategy Inc
F:MIGA
|
US |
|
T
|
Telefonaktiebolaget LM Ericsson
F:ERCG
|
SE |
|
ING Groep NV
AEX:INGA
|
NL |
|
B
|
Bandai Namco Holdings Inc
XMUN:N9B
|
JP |
Wall St Price Targets
HIK Price Targets Summary
Hikma Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for HIK is 1 938 GBX with a low forecast of 1 586.71 GBX and a high forecast of 2 257.5 GBX.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HIK's stock price target?
Price Target
1 938
GBX
According to Wall Street analysts, the average 1-year price target for HIK is 1 938 GBX with a low forecast of 1 586.71 GBX and a high forecast of 2 257.5 GBX.
What is the Revenue forecast for Hikma Pharmaceuticals PLC?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 5%.
What is the Gross Profit forecast for Hikma Pharmaceuticals PLC?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 5 years is 5%.
What is the Operating Income forecast for Hikma Pharmaceuticals PLC?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 8 years is 4%.
What is the Pre-Tax Income forecast for Hikma Pharmaceuticals PLC?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 7%.
What is the Net Income forecast for Hikma Pharmaceuticals PLC?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Net Income has been 13%. The projected CAGR for the next 5 years is 9%.